Pfizer-BioNTech COVID-19 Vaccine
for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination.

- If a person moves from a younger age group to an older age group during the primary series, they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

### Children who turn from age 4 to age 5 years

**Recommended:** Children who started a primary series and turned from age 4 to age 5 years between dose 1 and dose 2 in the primary series should receive:

- **Dose 1 (Age 4):** 0.20 mL (3 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border)
- **Dose 2 (Age 5):** 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)
- **Dose 3 (Age 5):** 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)

**Reason:** The child turns 5.

**Recommended:** Children who started a primary series and turned from age 4 to age 5 years between dose 2 and dose 3 in the primary series should receive:

- **Dose 1 (Age 4):** 0.20 mL (3 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border)
- **Dose 2 (Age 4):** 0.20 mL (3 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border)
- **Dose 3 (Age 5):** 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)

**Reason:** The child turns 5.

**Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

- A 2-dose primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years (orange cap and label border)

**Dose 1: Age 4**

Dose 2: Age 4 or 5

3-8 weeks
Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group

A 3-dose primary series initiated with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years (maroon cap and label border). Each of doses 2 and 3 may be with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years (maroon cap and label border), or the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years (orange cap and label border).

Dose 1: Age 4
3-8 weeks

Dose 2: Age 4 or 5
OR

Dose 3: Age 5
OR

Children who turn from age 11 years to 12 years

**Recommended:** Children who started a primary series and turned from age 11 to age 12 years before completion of the series should receive:

- **Dose 1 (Age 11):** 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)

  - 3-8 weeks

- **Dose 2 (Age 12):** 0.30 mL (30 mcg) of the product authorized for children ages 12–17 years (gray cap and label border)

  - Child turns 12

**Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

**Either dose may be:**
- 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border), or
- 0.30 mL (30 mcg) of the product authorized for children ages 12–17 years (gray cap and label border)

- **Dose 1: Age 11**
  - OR

  - 3-8 weeks

  - OR

- **Dose 2: Age 12**
  - OR